Viewing Study NCT02453594


Ignite Creation Date: 2025-12-25 @ 1:43 AM
Ignite Modification Date: 2026-04-23 @ 9:13 AM
Study NCT ID: NCT02453594
Status: COMPLETED
Last Update Posted: 2024-10-29
First Post: 2015-05-21
Is Gene Therapy: True
Has Adverse Events: True

Brief Title: Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)
Sponsor: Merck Sharp & Dohme LLC
Organization: